← Leaderboards
Barney S Graham
Vanderbilt University
$269,836
Attributed
$269,836
Total exposure
18
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$269,836 · 18
By mechanism
R01$267,468 · 1
M01$2,368 · 17
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Peter F Wright$12,188,551
- Christopher R Aiken$23,132,488
- Nancy J Olsen$6,548,556
- Sebastian Joyce$13,492,547
- Karl W Boehme$4,459,143
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectAids VaccinesHuman Therapy EvaluationDrug Screening /EvaluationHiv Envelope Protein Gp120Human Immunodeficiency Virus 1Clinical Trial Phase IVaccine DevelopmentVector VaccineGag ProteinPoxviridaeAids TherapyRecombinant ProteinsRecombinant VirusImmunomodulatorsActive ImmunizationHiv InfectionsOutcomes ResearchAntigen Antibody ReactionHiv Envelope Protein Gp41Adult Human (21+)Live VaccinePlacebos
Grant awards (78)
SAFETY AND REACTOGENICITY OF HIV-1 SF2$0
M01 · FY2002 · RR
EVALUATE HIV 1 SF2 RECOMBINANT TP24 SUBUNIT VACCINE (CHIRON VACCINES)$0
M01 · FY2002 · RR
TRIAL OF HIV 1 GP120C4 V3 HYBRID POLYVALENT PEPTIDE IMMUNOGEN IN MINERAL OIL$0
M01 · FY2002 · RR
HIV 1 F2 RGP120 BIOCINE COMB W/ MF59 IN HIV 1 UNINFECTED$0
M01 · FY2002 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV IN HIV 1 UNINFECTED ADULT VOLUNTEER$0
M01 · FY2002 · RR
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS$0
M01 · FY2002 · RR
CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2002 · RR
IMMUNOGENICITY OF FACILITATED HIV 1 GAG/POL DNA VACCINE$0
M01 · FY2002 · RR
LIVE RECOMBINANT CANARYPOX WITH/WITHOUT HIV-1 SF2 RGP120 IN UNINFECTED VOLUNTER$0
M01 · FY2002 · RR
RECOMBINANT VACCINIA HIV 1 IIIB ENV/GAG/POL VACCINE$0
M01 · FY2002 · RR
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2$0
M01 · FY2002 · RR
PARTICIPANTS IN HIV 1 PHASE I &II VACCINE TRIALS WHO DEVELOP HIV 1 INFECTIONS$0
M01 · FY2002 · RR
ALVAC/HIV (VCP205) AND HIV1 SF 2 RGP120 IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2002 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS$0
M01 · FY2002 · RR
P24 VLP PARTICLES IN HIV1 SERONEGATIVE SUBJECTS$0
M01 · FY2002 · RR
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS$0
M01 · FY2001 · RR
IMMUNOGENICITY OF FACILITATED HIV 1 GAG/POL DNA VACCINE$0
M01 · FY2001 · RR
CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS$0
M01 · FY2001 · RR
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV IN HIV 1 UNINFECTED ADULT VOLUNTEER$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV IN HIV 1 UNINFECTED ADULT VOLUNTEER$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV IN HIV 1 UNINFECTED ADULT VOLUNTEER$0
M01 · FY2001 · RR
HIV 1 F2 RGP120 BIOCINE COMB W/ MF59 IN HIV 1 UNINFECTED$0
M01 · FY2001 · RR
HIV 1 F2 RGP120 BIOCINE COMB W/ MF59 IN HIV 1 UNINFECTED$0
M01 · FY2001 · RR
HIV 1 F2 RGP120 BIOCINE COMB W/ MF59 IN HIV 1 UNINFECTED$0
M01 · FY2001 · RR
TRIAL OF HIV 1 GP120C4 V3 HYBRID POLYVALENT PEPTIDE IMMUNOGEN IN MINERAL OIL$0
M01 · FY2001 · RR
TRIAL OF HIV 1 GP120C4 V3 HYBRID POLYVALENT PEPTIDE IMMUNOGEN IN MINERAL OIL$0
M01 · FY2001 · RR
TRIAL OF HIV 1 GP120C4 V3 HYBRID POLYVALENT PEPTIDE IMMUNOGEN IN MINERAL OIL$0
M01 · FY2001 · RR
EVALUATE HIV 1 SF2 RECOMBINANT TP24 SUBUNIT VACCINE (CHIRON VACCINES)$0
M01 · FY2001 · RR
EVALUATE HIV 1 SF2 RECOMBINANT TP24 SUBUNIT VACCINE (CHIRON VACCINES)$0
M01 · FY2001 · RR
EVALUATE HIV 1 SF2 RECOMBINANT TP24 SUBUNIT VACCINE (CHIRON VACCINES)$0
M01 · FY2001 · RR
SAFETY AND REACTOGENICITY OF HIV-1 SF2$0
M01 · FY2001 · RR
SAFETY AND REACTOGENICITY OF HIV-1 SF2$0
M01 · FY2001 · RR
SAFETY AND REACTOGENICITY OF HIV-1 SF2$0
M01 · FY2001 · RR
P24 VLP PARTICLES IN HIV1 SERONEGATIVE SUBJECTS$0
M01 · FY2001 · RR
P24 VLP PARTICLES IN HIV1 SERONEGATIVE SUBJECTS$0
M01 · FY2001 · RR
P24 VLP PARTICLES IN HIV1 SERONEGATIVE SUBJECTS$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS$0
M01 · FY2001 · RR
ALVAC/HIV (VCP205) AND HIV1 SF 2 RGP120 IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
ALVAC/HIV (VCP205) AND HIV1 SF 2 RGP120 IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
ALVAC/HIV (VCP205) AND HIV1 SF 2 RGP120 IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2001 · RR
PARTICIPANTS IN HIV 1 PHASE I &II VACCINE TRIALS WHO DEVELOP HIV 1 INFECTIONS$0
M01 · FY2001 · RR
PARTICIPANTS IN HIV 1 PHASE I &II VACCINE TRIALS WHO DEVELOP HIV 1 INFECTIONS$0
M01 · FY2001 · RR
PARTICIPANTS IN HIV 1 PHASE I &II VACCINE TRIALS WHO DEVELOP HIV 1 INFECTIONS$0
M01 · FY2001 · RR
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2$0
M01 · FY2001 · RR
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2$0
M01 · FY2001 · RR
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2$0
M01 · FY2001 · RR
RECOMBINANT VACCINIA HIV 1 IIIB ENV/GAG/POL VACCINE$0
M01 · FY2001 · RR
RECOMBINANT VACCINIA HIV 1 IIIB ENV/GAG/POL VACCINE$0
M01 · FY2001 · RR
RECOMBINANT VACCINIA HIV 1 IIIB ENV/GAG/POL VACCINE$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARYPOX WITH/WITHOUT HIV-1 SF2 RGP120 IN UNINFECTED VOLUNTER$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARYPOX WITH/WITHOUT HIV-1 SF2 RGP120 IN UNINFECTED VOLUNTER$0
M01 · FY2001 · RR
LIVE RECOMBINANT CANARYPOX WITH/WITHOUT HIV-1 SF2 RGP120 IN UNINFECTED VOLUNTER$0
M01 · FY2001 · RR
IMMUNOGENICITY OF FACILITATED HIV 1 GAG/POL DNA VACCINE$0
M01 · FY2001 · RR
IMMUNOGENICITY OF FACILITATED HIV 1 GAG/POL DNA VACCINE$0
M01 · FY2001 · RR
RSV INDUCED PATTERN OF CYTOKINE EXPRESSION AND DISEASE$267,468
R01 · FY2000 · AI
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS$592
M01 · FY2000 · RR
RECOMBINANT ENVELOPE PROTEIN HIV1 F2 RGP120 WITH MF59$592
M01 · FY2000 · RR
CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS$592
M01 · FY2000 · RR
LIVE RECOMBINANT CANARYPOX ALVAC HIV VC205 COMBINED WITH MGCSF$592
M01 · FY2000 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS$0
M01 · FY2000 · RR
P24 VLP PARTICLES IN HIV1 SERONEGATIVE SUBJECTS$0
M01 · FY2000 · RR
SAFETY AND REACTOGENICITY OF HIV-1 SF2$0
M01 · FY2000 · RR
EVALUATE HIV 1 SF2 RECOMBINANT TP24 SUBUNIT VACCINE (CHIRON VACCINES)$0
M01 · FY2000 · RR
TRIAL OF HIV 1 GP120C4 V3 HYBRID POLYVALENT PEPTIDE IMMUNOGEN IN MINERAL OIL$0
M01 · FY2000 · RR
HIV 1 F2 RGP120 BIOCINE COMB W/ MF59 IN HIV 1 UNINFECTED$0
M01 · FY2000 · RR
LIVE RECOMBINANT CANARY POX ALVAC HIV IN HIV 1 UNINFECTED ADULT VOLUNTEER$0
M01 · FY2000 · RR
IMMUNOGENICITY OF FACILITATED HIV 1 GAG/POL DNA VACCINE$0
M01 · FY2000 · RR
LIVE RECOMBINANT CANARYPOX WITH/WITHOUT HIV-1 SF2 RGP120 IN UNINFECTED VOLUNTER$0
M01 · FY2000 · RR
RECOMBINANT VACCINIA HIV 1 IIIB ENV/GAG/POL VACCINE$0
M01 · FY2000 · RR
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2$0
M01 · FY2000 · RR
PARTICIPANTS IN HIV 1 PHASE I &II VACCINE TRIALS WHO DEVELOP HIV 1 INFECTIONS$0
M01 · FY2000 · RR
ALVAC/HIV (VCP205) AND HIV1 SF 2 RGP120 IN HIV 1 UNINFECTED ADULT VOLUNTEERS$0
M01 · FY2000 · RR